EGFR and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma (HNSCC), studies found that the combination of the epidermal growth factor receptor (EGFR) inhibitor cetuximab and the PARP-1 inhibitor olaparib produces significant synergistic radiosensitizing effects.